CADTH

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Name of drug and indication under review:		Dr. Sasha Lupichuk			
		Palbociclib in combination with fulvestrant for metastatic breast cancer			
С	onflict of Interest Declaration				
co of	inflicts of interest. A registered clinician must dec	ODR process, all participants in the pCODR review process must disclose any lare any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or			
Ex	amples of conflicts of interest include, but are no	t limited to:			
٠	financial support from the pharmaceutical industifits, and salary)	try or other entities (e.g., educational or research grants, honoraria,			
•	affiliations, or personal or commercial relationsh	ips with drug manufacturers or other interest groups.			
Se	ection A: Payment Received				
1.	Have you received any payments over the pre- indirect interest in the drug under review?	vious two years from any company or organization that may have a direct or			
	⊠ Yes □ No				
	If no, please go to Section B.				
2.	What form of payment did you receive? (Check	all that apply.)			
÷					
	☐ Conference attendance	☐ Research/educational grants			
	☐ Royalties	☐ Travel grants			
	☐ Gifts	☐ Sponsorship of events			
	☐ Honoraria	☐ Other, please specify:			
3.	Please provide the names of companies and or	ganizations, and the amounts of the payments, in the following box.			
	Novartis \$1000.				
		·			



Section B: Holdings or Other Interests

Have you received or are in may have a direct or indirect	n possession of stocks or options of more than \$ at interest in the drug under review? If yes, pleas	10,000 (excluding mutual funds) for organizations that se list them in the following box.
No		
Section C: Affiliations,	Personal or Commercial Relationships	
parent corporation, subsidia		alth technology manufacturer (including the manufacturer's other interest groups? If yes, please provide the names of nips, in the following box.
No		
hereby certify that I have dotential, or perceived confl	lisclosed all relevant information with respect to ict of interest situation.	any matter involving a Party that may place me in a real,
2018/10/04	Dr. Sasha Lupichuk	AL
Date	Name	Signature



Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Susan Ellard				
Palbociclib and fulvestrant				
CODR process, all participants in the pCODR review process must disclose any eclare any potential conflicts of interest that may influence or have the appearance at of interest declaration is requested for transparency — it does not negate or				
not limited to:				
stry or other entities (e.g., educational or research grants, honoraria, ships with drug manufacturers or other interest groups.				
revious two years from any company or organization that may have a direct or				
ck all that apply.)				
alth Program or Operating Funding ice) (e.g., website)				
☐ Research/educational grants				
☐ Travel grants				
☐ Sponsorship of events				
☐ Other, please specify:				
organizations, and the amounts of the payments, in the following box.				
a research advisory board with AZ almost 2 yrs ago, \$, on a day that ys to attend. The discussion was not in reference to fulvestrant or breast cance				



Section B: Holdings o	Other Interests				
	lave you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that any have a direct or indirect interest in the drug under review? If yes, please list them in the following box.				
по					
Section C: Affiliations,	Personal or Commercial Relationship	s			
parent corporation, subsidi	o you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's arent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of e companies and organizations, and outline the nature of these relationships, in the following box.				
no					
I hereby certify that I have potential, or perceived con		to any matter involving a Party that may place me in a real,			
12/9/2018	Susan Ellard	mund			
Date	Name	Signature			

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:

Dr. Sandeep Sehdev

Name of drug and indication under review:

Palbociclib (Ibrance) in combination with fulvestrant for Metastatic Breast Cancer

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1.	Have you received any payments over the previous two years from any company or
	organization that may have direct or indirect interest in the drug under review?
	Y Vos

X Yes No

If no, please go to Section B

2.	What form of payment did you receive? (Check all that apply.)				
	X	Advisory board		Program or Operating Funding (e.g., website)	
	X	Conference attendance		Research/educational grants	
		Royalties		Travel grants	
		Gifts		Sponsorship of Events	
		Honoraria		Other please specify:	

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Pfizer - advisory boards: \$\frac{1}{2}\frac{

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No	

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No		

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Oct 8/18

Name: Dr. Sandeep Sehdev

Signature:



pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Andrea Eisen

Name of drug and indication under review: palbociclib + fulvestrant/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary,
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes ₁□√No If no, please go to Section B. 2. What form of payment did you receive? (Check all that apply.) Advisory role (e.g., advisory boards, Program or Operating Funding HTA submission advice) (e.g., website) Research/educational grants Conference attendance Royalties \Box Travel grants Gifts Sponsorship of Events Honoraria Other, please specify: Click here to enter text.

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

Click here to enter text. Any Tulif

Name:

Click here to enter text.

Signature:

Click here to enter text.

A Gusen (Andrea Elsen)

Our cancer centre has partupoled in

perturumals. I have not permally

received any compensation related to



pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Annie Ngan

Name of drug and indication under review: palbociclib + fulvestrant/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Se	ction A: Payment	Received			
1.	Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?				
	☐ Yes	⊠ No			
	If no, please go to	Section B.			

What form of payment did you receive? (Check all that apply.)						
	Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)			
	Conference attendance		Research/educational grants			
	Royalties		Travel grants			
	Gifts		Sponsorship of Events			
☐ Honoraria						
	Other, please specify: Click here to enter text.					

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text.

2.



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

April 6th, 2018

Name:

Annie Ngan

Signature:

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Phillip Blanchette

Name of drug and indication under review: palbociclib + fulvestrant/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts

int				fluencing the information submitted. Conflict of s not negate or preclude the use of the clinician				
•	 Examples of conflicts of interest include, but are not limited to: financial support from the pharmaceutical industry or other entities e.g., educational or research grants honoraria, gifts, and salary; affiliations or personal or commercial relationships with drug manufacturers or other interest groups. 							
	Have orga □ Ye	A. Fayment Received byou received any payments over the p nization that may have direct or indirect s No please go to Section B.		• • • •				
2.	Wha	t form of payment did you receive? (Ch	neck all t	that apply.)				
		Advisory role (e.g., advisory boards, HTA submission advice) Conference attendance Royalties Gifts Honoraria		Program or Operating Funding (e.g., website) Research/educational grants Travel grants Sponsorship of Events				
		Other, please specify: Check here to enter	er text					
3.	in th	se provide the names of companies and e box below.	d organi	izations and the amounts of the payments				



seems 21 studyings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

sensits additions personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

April 10 2018

Name:

Phillip Blanchette

Signature:



pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Orit Freedman

Name of drug and indication under review: palbociclib + fulvestrant/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- · affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

se	ection A: Payment Received					
1.	Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?					
	☐ Yes	s ⊠ No				
	If no, p	please go to Section B.				
2.	What form of payment did you receive? (Check all that apply.)					
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)		
		Conference attendance		Research/educational grants		
		Royalties		Travel grants		
		Gifts		Sponsorship of Events		
	☐ Honoraria					
	☐ Other, please specify: Click here to enter text.					

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text.



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

no

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I have participated in a clinical trial with this medication

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

12/04/18

Name:

Orit Freedman

Signature:

OF



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Karen King

Name of drug and indication under review: Palbociclib with Fulvestrant

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Sec 1.	ction A: Payment Received Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes ☑ No				
	If no, please go to Section B.				
2.	What f	What form of payment did you receive? (Check all that apply.)			
		Advisory role (e.g., advisory boards, HTA submission advice) Conference attendance Royalties Gifts Honoraria		Program or Operating Funding (e.g., website) Research/educational grants Travel grants Sponsorship of Events	
		Other, please specify: Click here to enter text.			
3.	Please provide the names of companies and organizations and the amounts of the payments				

Click here to enter text.

in the box below.



Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: April 30, 2019

Name: Karen King

Signature: Click John enter text